Research capsule

STUDY CLAIM: Pycnogenol significantly reduces diabetic microangiopathy, which is responsible for major diabetic health complications.

PUBLISHED: Cesarone MR, et al. Rapid relief of signs/symptoms in chronic venous microangiopathy with pycnogenol: a prospective, controlled study. Angiology 2006 Oct-Nov;57(5):569-76.

ABSTRACT: The aim of this study was to investigate the clinical efficacy of oral Pycnogenol in patients with severe chronic venous insufficiency. Patients with severe venous hypertension (chronic venous insufficiency, ankle swelling) and history of venous ulcerations were treated with Pycnogenol (50mg capsules, three times daily for a total of 150mg daily) for eight weeks. A group of 21 patients was included in the treatment group and 18 equivalent patients were observed as controls. All 21 patients (age 53 years; range, 42-60 years) in the treatment group completed the eight-week study. Also, the 18 controls completed the follow-up period. There were no drop-outs.

The average ambulatory venous pressure was 59.3 (SD 7.2; range 50-68) with a refilling time shorter than 10 seconds (average 7.6; SD 3). There were no differences in ambulatory venous pressure or refilling time between the treatment and control patients. The duration of the disease, from the first signs/symptoms, was on average 5.7 years (SD 2.1). At four and eight weeks, in all Pycnogenol-treated subjects, microcirculatory and clinical evaluations indicated a progressive decrease in skin flux, indicating an improvement in the level of microangiopathy; a significant decrease in capillary filtration; a significant improvement in the symptomatic score; and a reduction in edema. There were no visible effects in controls.

In conclusion, this study confirms the fast clinical efficacy of Pycnogenol in patients with chronic venous insufficiency and venous microangiopathy. The study indicates the significant clinical role of Pycnogenol in the management, treatment and control of this common clinical problem. The treatment may be also useful to prevent ulcerations by controlling the level of venous microangiopathy.

POTENTIAL APPLICATIONS: Pycnogenol is available as a supplemental ingredient for a wide diversity of health conditions.

MORE INFO:
+ 1 877 369 9934
www.pycnogenol.com

STUDY CLAIM: Protandim reduces oxidative stress by increasing endogenous enzymatic actions that deactivate reactive oxygen molecules.

PUBLISHED: Nelson SK, et al. The induction of human superoxide dismutase and catalase in vivo: a fundamentally new approach to antioxidant therapy. Free Radical Biol Med 2006;40:341-7.

ABSTRACT: Antioxidant compounds, which are usually taken orally in foods or as supplements, react stoichiometrically with reactive oxygen molecules and, therefore, are limited by how many oxygen species can be deactivated per antioxidant molecule. On the other hand, certain enzymes already in the body, such as superoxide dismutase (SOD) and catalase (CAT), deactivate reactive oxygen molecules continuously without being used up.

A 675mg/day composition consisting of extracts of five widely studied medicinal plants (Protandim) was administered to healthy human subjects ranging in age from 20-78 years. Each ingredient was present at a dosage sufficiently low to avoid any accompanying unwanted pharmacological effects. Blood was analysed before supplementation and after 30 and 120 days of supplementation. Erythrocytes were assayed for SOD and catalase, and plasma was assayed for lipid peroxidation products as thiobarbituric acid-reacting substances (TBARS), as well as uric acid, C-reactive protein, and cholesterol (total, LDL and HDL).

Before supplementation, TBARS showed a strong age-dependent increase. After 30 days, TBARS declined by an average of 40 per cent and the age-dependent increase was eliminated. By 120 days, erythrocyte SOD increased by 30 per cent and catalase by 54 per cent. We conclude that induction of the catalytic antioxidants SOD and catalase may be a more effective approach than supplementation with antioxidants (such as vitamins C and E) that can, at best, stoichiometrically scavenge a very small fraction of total oxidant production.

POTENTIAL APPLICATIONS: Protandim ia available as a finished-good supplement. Safe modification of oxidative stress may prove to be a clinically beneficial means of decreasing oxidative stress associated with human disease.

MORE INFO:
+ 1 720 488 1711
www.protandim.com

Hide comments

Comments

  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Publish